Cytokinetics CEO reports 97,926-share trust sale
CYTOKINETICS CEO Robert Blum exercised stock options, sold shares under a Rule 10b5-1 plan, and oversaw sizable gifts and trust transfers where he disclaims beneficial ownership.
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) reported multiple insider transactions by President and CEO Robert I. Blum and related trusts. On September 14, 2026, he exercised options for 7,500 shares of common stock at $10.60 per share under a pre-arranged Rule 10b5-1 trading plan and sold those 7,500 shares at $73.44 per share the same day under the same plan. The filing also reports charitable gifts and transfers totaling over 190,000 shares, including a transfer of 97,926 shares to The Bridget Blum 2026 Irrevocable Trust, where he is co-trustee and disclaims beneficial ownership. On September 15, 2026, that trust sold 97,926 shares at $69.33 per share, with Blum disclaiming any beneficial interest in the shares sold or proceeds.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
9 txns
Insider
Blum Robert I
Role
President & CEO
Sold
105,426 shs ($7.34M)
Approx. gross sale proceeds
$7.34M
Approx. exercise cost
$80K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F6 | 97,926 | $69.33 | $6.79M |
| Exercise | Non-Qualified Stock Option (Right to Buy) F9 | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,500 | $10.60 | $80K |
| Sale | Common Stock F2 | 7,500 | $73.44 | $551K |
| Gift | Common Stock F3 | 1,350 | $0.00 | $0.00 |
| Gift | Common Stock F4 | 97,926 | $0.00 | $0.00 |
| Gift | Common Stock F5 | 97,926 | $0.00 | $0.00 |
| holding | Common Stock F7 | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 156,745 contracts (Direct);
Common Stock — 278,544 shares (Direct);
Common Stock — 0 shares (Indirect, by Trust 3. Beneficial Ownership Disclaimed.);
Common Stock — 2,083 shares (Indirect, by Trust 1. Beneficial Ownership disclaimed.);
Common Stock — 2,083 shares (Indirect, by Trust 2. Beneficial Ownership Disclaimed.)
Footnotes (9)
- F1. Acquisition of shares of common stock upon exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).
- F2. Sale of shares of common stock acquired upon exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).
- F3. Charitable gift.
- F4. Transfer of shares of common stock to The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares held by the aforementioned trust upon completion of the gift transfer.
- F5. Acquisition of shares by The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares held by the aforementioned trust.
- F6. Sale of shares of common stock by The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares sold or the proceeds thereof.
- F7. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
- F8. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
- F9. Exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).
Key Figures
Shares sold by related trust: 97,926 shares
Sale price by related trust: $69.33 per share
Option exercise shares: 7,500 shares
+5 more
8 metrics
Shares sold by related trust
97,926 shares
Sale of CYTOKINETICS common stock by The Bridget Blum 2026 Irrevocable Trust on September 15, 2026
Sale price by related trust
$69.33 per share
Price received for 97,926 CYTOKINETICS shares sold by the 2026 trust on September 15, 2026
Option exercise shares
7,500 shares
Common shares acquired from exercising non-qualified stock options on September 14, 2026
Option exercise price
$10.60 per share
Exercise price for 7,500 non-qualified stock options converted into CYTOKINETICS common stock
Shares sold after exercise
7,500 shares
Common shares sold on September 14, 2026 that were acquired from the same-day option exercise
Sale price after exercise
$73.44 per share
Price received for 7,500 CYTOKINETICS shares sold on September 14, 2026 under a Rule 10b5-1 plan
Charitable gift
1,350 shares
Bona fide charitable gift of CYTOKINETICS common stock on September 14, 2026
Remaining options in series
156,745 options
Non-qualified stock options reported as outstanding after the September 14, 2026 exercise
Key Terms
Non-Qualified Stock Option, Rule 10b5-1(c), bona fide gift, Irrevocable Trust
4 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1(c) regulatory
"intended to satisfy the conditions of Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
bona fide gift financial
"Bona fide gift."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Irrevocable Trust financial
"The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option exercise did CYTK CEO Robert Blum report in this Form 4?
Robert Blum exercised 7,500 stock options for CYTOKINETICS common stock on September 14, 2026 at an exercise price of $10.60 per share, converting them into an equal number of common shares under a pre-arranged Rule 10b5-1 trading plan.
Were Robert Blum’s CYTK transactions made under a Rule 10b5-1 plan?
Yes. Footnotes state the option exercise and related sale of 7,500 shares of CYTOKINETICS common stock were carried out under a trading plan adopted by Robert Blum and intended to satisfy the conditions of Rule 10b5-1(c).
What gifts of CYTK stock did Robert Blum report?
The filing reports a charitable gift of 1,350 shares of CYTOKINETICS common stock and a 97,926-share gift transfer to The Bridget Blum 2026 Irrevocable Trust on September 14, 2026. Robert Blum is a co-trustee of that trust and disclaims beneficial ownership of its shares.
How many CYTK options remain after Robert Blum’s exercise?
After exercising 7,500 options on September 14, 2026, the position in that non-qualified stock option series shows 156,745 options remaining, according to the reported post-transaction derivative holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
